Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Topical use (cosmetic ingredient) | Extensive, long-standing; legal cosmetic status, not a trial program |
| Injectable/subQ human trials | None identified at meaningful scale |
| Cell-culture and animal wound models | Substantial, the strongest controlled evidence that exists |
| Mechanistic plausibility | Reasonably strong - collagen, elastin, GAG synthesis pathways |
| Regulatory status | Legal cosmetic ingredient (topical); unapproved research chemical (injectable) |
What GHK-Cu Is
GHK-Cu is the copper-bound complex of GHK (glycyl-L-histidyl-L-lysine), a small tripeptide that occurs naturally in human plasma, saliva, and urine, and whose concentration declines with age. It's studied for its ability to stimulate collagen and glycosaminoglycan synthesis, attract repair cells, and support wound healing and tissue remodeling. It's sold in two very different forms that carry very different evidence standards: a topical cosmetic ingredient, labeled copper tripeptide-1, and an injectable or subcutaneous research chemical.
Human Evidence, By Route
Topical GHK-Cu has extensive, long-standing use in cosmetic formulations, and there's a real body of cosmetic-science literature examining its effects on skin. That's genuine human experience at scale, but it's a different evidentiary standard than a drug trial: the FDA does not require premarket approval for cosmetic ingredients marketed with appearance-related claims, so widespread topical use reflects cosmetic-ingredient status rather than a completed clinical trial program with placebo control and blinded outcome measurement.
Injectable or subcutaneous GHK-Cu sits in a much thinner position. No dedicated, large-scale human trials of the injectable route have been identified. Its proposed benefits for that route are extrapolated from the topical cosmetic data and from cell-culture and animal wound-healing models, not confirmed by trials of the injectable product itself.
Why the distinction matters: a compound's name doesn't carry one evidence level across every way it's sold. GHK-Cu's topical form has real-world human usage history behind it; its injectable, research-chemical form does not, and the two shouldn't be assumed interchangeable just because they share a name.
Preclinical and Mechanistic Evidence
Preclinical and mechanistic research supports GHK-Cu's proposed activity: it has been shown to increase synthesis of collagen, elastin, glycosaminoglycans, and related extracellular matrix components, alongside anti-inflammatory and cell-attracting effects that support tissue repair. Most of the strongest controlled data comes from cell-culture and animal wound models rather than large randomized human trials.
Evidence Gaps and Regulatory Status
GHK-Cu has never been FDA-approved as a therapeutic drug for any indication, in either form. Topical GHK-Cu (copper tripeptide-1) is legal and widely sold as a cosmetic ingredient under that framework specifically. Injectable GHK-Cu is not a cosmetic product and is not FDA-approved; it is not currently on the FDA's 503A bulk drug substances list and is scheduled for a future FDA compounding advisory committee review. What would close the gap for the injectable route is the same thing missing for most compounds in this series: dedicated, controlled human trials of that specific product, rather than data borrowed from the topical form or from animal models.
Bloodwork to Track
There's no single bloodwork marker specific to GHK-Cu. A general safety baseline, comprehensive metabolic panel and CBC, is a reasonable starting point before and during any protocol involving the injectable form. See the peptide bloodwork guide for what a baseline panel typically includes.
Related Reading
For dosing by route and the full regulatory breakdown, see the GHK-Cu reference page. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.